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Summary.-Women who had used oral contraceptives, particularly long-term users,
were found to have higher rates of malignant melanoma and of a past history of
skin cancer than those who had never used oral contraceptives. This excess was
confined to lesions of the lower limb. The association between oral contraceptive use
and melanoma was noted in 3 separate sets of data, although it was statistically
significant only in one. The possibility that this relationship is indirect because, for
example, oral contraceptive users are more likely than never-users to be exposed
to sunlight and thus to develop malignant melanoma, cannot be excluded.
HYPERPIGMENTATION, especially of the
face, was one of the first reported and is
one of the more common side-effects of
oral contraceptive (OC) use (Cook, Gamble
and Satterthwaite, 1961; Jelinek, 1970).
There is marked regional variation in the
reported incidence of chloasma, it being
particularly frequent in sunny climates
(Jelinek, 1970; Koide and Lyle, 1975;
Carruthers, 1966, 1967). Its incidence
increases with duration of OC use (Car-
ruthers, 1966). The mechanisms of the
pigmentary changes are not fully under-
stood. Animal experiments carried out by
Snell and Bischitz (1960) have shown
that oestrogens and oestrogen-proges-
togen combinations cause an increase both
in melanocyte count and also in intra-
cellular and extracellular melanin content.
Although oestrogen is a major stimulant
of melanogenesis, its effect is greatly
augmented by the simultaneous adminis-
tration of progestogens. These effects are
thought to be due to direct action of the
hormones on the melanocyte, but it is
also possible that the hormones act in-
directly by stimulating the pituitary to
secrete melanocyte-stimulating hormone.
Because of the hormonal control of
pigmentation, the possibility that OC use
may predispose to the development of
malignant melanoma was suggested by
Ellerbroek (1968). This relationship was
further investigated in a population of
women who were members of the Kaiser-
Permanente Health Plan in Walnut Creek,
a suburb of the San Francisco Bay Area
in California. The preliminary findings,
although based on small numbers, are
reported here.
STUDY POPULATION AND METHODS
The relationship of malignant melanoma
to OC use was studied in two separate groups
of women. In the first, Group A, incidence
andmortalityratesfrommalignantmelanoma
and the proportion reporting a past history
of skin cancer were compared in users and
nonusers of OCs. In the second, Group B, a
comparison of OC use in women with malig-
nant melanoma and in matched controls was
performed.
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Group A.-Between December 1968 and
February 1972, 17,942 women aged 17-59
living in the Walnut Creek Health Plan area
and members of the Kaiser Foundation
Health Plan were recruited into an ongoing
prospective study designed to evaluate the
noncontraceptive effects of OCs. The charac-
teristics of this middleclass, predominantly
(97%) white population have been reported
by Ramcharan (1974).
Data on the occurrence of skin cancer in
this population were obtained in several ways.
At entry into the study each woman was
asked, along with other questions, about a
past history ofskin cancer. During the follow-
up period, new cases of malignant melanoma
were identified from the tumour registers of
the Pathology Department in Kaiser-Perma-
nente Medical Center, Walnut Creek. Twenty-
two new cases were diagnosed, and a copy of
the pathologist's report was obtained for all
these.
The person-years at risk were calculated
from each woman's date of entry into the
study until 30 June 1976, for those who were
still Kaiser Health Plan members, or to the
date of termination of Health Plan member-
ship for the 2461 women whose Health Plan
coverage ceased before that date. The total
period of observation was approximately
90,000 person-years. Age-adjusted mortality
rates were calculated by indirect standardi-
zation, on the basis of the distribution of
person-years in the total population.
Data on oral contraceptive, oestrogen, and
other hormone use were elicited by a question-
naire completed by each woman at entry into
the study. Data on subsequent OC and other
hormone use were obtained from question-
naires sent bymail, administered bytelephone
or included as part of a more detailed
questionnaire filled out at the time of
subsequent routine multiphasic examination.
For the analyses presented here, duration of
OC use was calculated by combining all these
data into a month-by-month calendar of OC
use for each woman. Because data on recent
OC use were incomplete, the duration of OC
use was calculated only up to June 1975.
Women who reported either OC use or
ostrogen use were classified as OC users
(there were no cases who reported use of
both). Data on other factors such as age,
parity, eye colour, past health, etc. were
obtained from the questionnaires completed
at entry into the study.
Group B.-From tumour registers of the
Kaiser-Permanente Medical Center's Patho-
logy Department in Walnut Creek, 37 women
were identified who were not members of
Group A and for whom malignant melanoma
was first diagnosed between 1 January 1968,
and 30 June 1976. These women were aged
20-59 at the time of diagnosis. Two controls,
matched to within one year of birth of
the cases, were chosen at random from a
special computerized file of female members
of the Kaiser Health Plan. The outpatient
records for all cases and controls were
obtained. A trained clerk, who was unaware
which records belonged to cases and controls
examined a section of each record. For the
cases, this section covered the period preced-
ing any mention of a suspicious pigmented
mole or melanoma; for the controls, it
covered the period corresponding to that of
the index case. Along with information on
year of birth and parity, the clerk noted all
references to OC and oestrogen use, including
date of each prescription and brand used.
Each woman was then coded, without know-
ledge of the diagnosis, as an "ever-user" or
"never-user" of OCs and oestrogens or as"no
information available". Seven cases and 15
controls were coded as "no information avail-
able" and direct mail or telephone contact
with them was attempted. All but 2 cases
and 5 controls were contacted in this way.
To assess the validity of the data extracted
from the medical records, a sub-sample of
the study population was contacted by mail.
For all but one of the 9 who replied, the
reported history of OC and oestrogen use
corresponded tothatwhich had beenextracted
from their records. The discrepancy arose
from one case who reported that she had
used OCs in the past, but she had been classi-
fied as a "never-user" according to the infor-
mation in her medical records.
RESULTS
Group A. Table I shows the number
of new cases of malignant melanoma
diagnosed during the study period, and
the incidence rates per 100,000 woman-
years by age ofthe woman at entry to the
study and by OC and oestrogen use. No
melanomas were diagnosed at age 15-24.
Except at age 35-44, the incidence rate
of malignant melanoma was higher in
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TABLE I.-Incidence Rate of Malignant Melanoma per 100,000 Woman-years, by Age at
Entry and History of Oral Contraceptive (OC) or Other Oestrogen Use
(Group A)
(The numbers of cases are shown in parentheses)
Oral contraceptive/oestrogean use
Ever-users of OCs
Age at
entry
23-34
35-44
45-54
25-54
(Age-adjusted)
Never use(Il
either
00 (0)
28-4 (:3)
24 - 1 (2)
17-6 (5)
Of less than
4 years
duration
21-3 (3)
30 7 (3)
35-0 (2)
24-1 (8)
Of more than
4 years
dluratioll
39-7 (4)
16 4 (1)
40-2 (1)
293-t (6)
Ever-users of
oestrogens
other thai
OCs
3.5 (3)
:32-2 (3)
All x oinen
24-0 (7)
25 1 (7)
36-5 (8)
23 9 (22)
OC users than never-users, especially in
those who had used OCs for 4 years or
more. The incidence of melanoma was also
higher in oestrogen users than in never-
users. None of these differences was
statistically significant.
The relationships of melanoma to other
factors, including parity, marital status,
education, smoking habits, eye colour, a
history ofhypertension or diabetesandthe
useoftranquillizers,weight-reducing medi-
cines, thyroid extracts or antihypertensive
agents, were examined. The well-known
increased risk of malignant melanoma
among those with light-coloured eyes
compared to those with brown eyes
(Lancaster and Nelson, 1957)was apparent.
But for both eye colours an increased
incidence of malignant melanoma among
OC users was noted. No other factors
appeared to be associated with the
development of melanoma.
There were 3 deaths from malignant
melanoma during the study period. Two
of these had been diagnosed before the
women entered the study. All deaths were
among OC users.
A history of malignant cancer of the
skin was reported by 164 women. The age-
adjusted rates for those with a history of
malignant tumors are shown in Table II.
OCusers, particularlythosewithaduration
of use of 4 years or more, reported higher
rates of malignant skin tumours. Users of
oestrogens and of other hormones also re-
ported slightly higher rates of these tum-
TABLE II. Aye-adjusted Rates per 1000
Women of Past History of Skin Cancer
by Oral Contraceptive (OC) or Other
Oestrogen Use at Entry into the Study
(Group A)
(The numbers of cases are showni in
parentheses)
Ever-users of OCs
Never-iiusers 0-4 Years 4-1 Years
7 8 (48) 9-4 (57) 14-6 (34)
Users of
oestrogens
other thai
OCs
8-.7 (25)
Chi-squiaredt for heterogenieity (3 d.f.) = 10 1
(P < 0 05).
ours. The date ofoccurrence ofthe cancers
was notr ecorded. Thus it is not possible to
determine whether the tumours developed
before or subsequent to hormone use.
Group B. Table III shows the distri-
bution of cases and controls by ever-use
of OCs. An excess of OC use was found
among the melanoma cas-es, where the
estimated relative risk was I. 8: 1. Even
if the 2 cases for whom no information
was available were never-users of OCs,
and the 5 controls with no information
were OC users, the relative risk estimate
would still be greater than 1. Furthermore,
if the cases and controls were subdivided
according to age or parity, the relative
risk was similar for women aged 20-34
and 35-59, and for women ofhigh and low
parity. These differences were not, how-
ever, statistically significant.
Table IV shows for all persons with
melanoma the distribution of the site of
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TABLE III. Oral Contraceptive Use among
Women with Malignant Melanoma and
Matched Controls
Oral
contraceptive
use
Ever
Never
No information
Total
(Group B)
No. cases (%)
22 (60)
13 (35)
2 (5)
37 (100)
No. controls (% )
33 (45)
36 (49)
5 (7)
74 (101)
Relative risk.
(Ever-users:never-users) = 1 .8: 1.
the lesions, by OC and oestrogen use.
Data from Groups A and B were com-
bined in this table. The overall distribu-
tion ofthe lesions found in this population
is similar to that reported for women in
other studies (Lee and Yongehaiyudha,
1971). Ever-users of OCs or oestrogens
showed an excess of lesions of the lower
limbs.
The distribution of the type of OC,
including its oestrogen and progestogen
content, ever-used by those with malig-
nant melanoma was compared with that
used by those without melanoma. No
clear association was found between
brand of OC or its oestrogen or progesto-
gen content and the occurrence of malig-
nant melanoma.
DISCUSSION AND CONCLUSION
An excess of ever-users of oral contra-
ceptives, particularly long-term OC users,
was found among those with newly
diagnosed malignant melanoma, and also
among those with a past history of skin
cancer. The association was weak, but
was found in 3 separate sets of data. Only
the differences in past history of skin
cancer were statistically significant.
Although each set of data has its inherent
biases, the consistency of the findings
strengthens the overall conclusion that
there may be a real association between
OC use and the development of malignant
melanoma.
Even if an association between OC use
and malignant melanoma does exist, this
does not necessarily imply causality. OC
users may, because of their behavioural
or other personal characteristics, be especi-
ally prone to develop malignant mela-
noma. Lancaster and Nelson (1957) re-
ported that those with a fair complexion,
with blue, green, orgrey eyes, or those who
spend more than 2 hours out ofdoors each
day are more likely to develop malignant
melanoma than those with darker com-
plexions, brown eyes or who spend less
than 2 hours out ofdoors each day. In this
study, a relationship between eye colour
and melanoma incidence was also noted,
but this could not explain the increased
ratesfound amongOCusers.Unfortunately,
no measure ofoutdoor activity or exposure
to sunlight is available in the populations
studied. If the majority of those with a
past history of skin cancer had developed
their malignancies before OC use, this
would suggest that OC ever-users and
never-users differed in their susceptibility
to skin cancer even before they began
using OCs. Because of the higher rates in
TABLE IV. Site ofPrimary Melanoma Lesions in Ever-users ofOral Contraceptives (OC)
or Other Oestrogens Compared with Never-users
(Groups A and B combined)
Site of lesion
Oestrogen use
OC
Other oestrogens
Never-users of OC or
oestrogens
No information
Total
/
No. on lower
limb (%)
14 (39)
4 (80)
3 (19)
2 (100)
23 (39)
No. on upper
limb (%)
10 (28)
O (0)
5 (31)
0 (0)
16 (27)
No. on trunk (%)
5 (14)
1 (20)
5 (31)
0 (0)
10 (17)
No. on head
and neck (%0)
7 (19)
0 (0)
3 (19)
0 (0)
10 (17)
Total (%)
36 (100)
5 (100)
16 (100)
2 (100)
59 (100)
A
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long-term OC users, it would also suggest
that short-term and long-term OC users
differed in their susceptibility to skin
cancer. It is not possible to determine the
time sequence of events from the available
data, but it seems unlikely that a relation-
ship between the risk of skin cancer and
the duration of OC use would be due to
different characteristics of short-term and
long-term OC users.
Dermatologists and pathologists might
be more likely to diagnose malignant
melanoma in OC users than non-users.
Examination of the outpatient and in-
patient records revealed, however, that
OC use was not referred to, either in
dermatologists' consultations, in case his-
tories sent with the biopsy specimens, or
in the majority of hospital discharge
summaries, even when a history of OC
use could be discerned from the out-
patient records. Only in one case history
was there specific mention of OC use in
relation to the development of melanoma;
one patient described that she noticed
that a mole had begun to grow and change
soon after she began taking OCs. This
relationship was unexpected and so it
seems very unlikely that diagnostic biases
could account for the observed associa-
tions.
If the use of OCs or oestrogens did
result in a real increase in the risk of
developing malignant melanomas, then
one might expect that the incidence and
mortality rates from malignant melanoma
would have increased for young women
since the early 1960s, when the use of OCs
became widespread. In almost all Euro-
pean and North American countries for
which data have been analysed, both
mortality rates and incidence rates of
malignant melanoma have been increas-
ing, especially at younger ages (Magnus,
1973; Elwood and Lee, 1975). Although
these trends could in part be due to OC
and oestrogen use by women, alternative
causal explanations, such as an increase
in solar radiation resulting from the
depletion of the earth's ozone layer
(Scott, 1975) and changes in recreation
activities and clothing fashion (Lee and
Yongchiavudha, 1971) have been sUg-
gested.
It is biologically plausible that the
prolonged adnministration of hormones
should affect the risk of developing malig-
naint melanonma. This is because of the
known stimtilatorv action of oestrogens
and oestrogen-progestogen combinations
on melanocyte activity (Sinell and Bis-
chitz, 1960) the finding of oestrogen
receptors in malignant melanoma cells
(Fisher, Neifeld and Lippman, 1976), and
the report of differential survival between
parous and nulliparous women with mela-
noma (Hersey et al., 1977). The excess
malign-ant melanoma of lower limbs noted
among OC or oestrogen users is difficult
to interpret in biological terms, however.
It probablv does not reflect a difference
in exposure to sunlight between OC or
oestrogen users an(d never-users, as clinical
studies have repeatedly failed to demon-
strate any relationship) between the site of
occurrence of melanomas and the site
exposed to sunlight (Lanicaster and Nelson,
1957; Cellin, Kopf and Garfinkel, 1969;
Davis, Herron and McLeod, 1966). It
may be of some importance, as the recent
increases in melanoma incidence among
young women have been almost entirely
confined to lesions of the lower limbs (Lee
and Yongchaiyudha, 1971).
In conclusion, the observed associatioin
between OC use aind maligniiant melanoma
is uinlikely to be the result of diagnostic
biases, but could reflect differential expo-
sure to suinlight among OC users anid never-
users, or be a chance finding. It seems im-
portant that other relevant data should be
collected from different popt)lations.
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